Literature DB >> 17429058

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.

Toshiyuki Kawasaki1, Kotaro Ishihara, Yukio Ago, Akemichi Baba, Toshio Matsuda.   

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes nigrostriatal dopaminergic neurotoxicity and behavioral impairment in rodents, and previous studies suggest that nitric oxide and reactive oxygen species are involved in MPTP-induced neurotoxicity. The present study examines the effect of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, on MPTP-induced neurotoxicity in the striatum and substantia nigra pars compacta (SNc) of C57BL/6J mice. MPTP treatment (10 mg/kg s.c. x 4 with 2-h intervals) decreased dopamine levels and tyrosine hydroxylase immunostaining in the striatum and SNc. Pretreatment with edaravone (1 and 3 mg/kg i.p.) significantly reduced the neurotoxicity in the SNc but not striatum. An immunohistochemical study showed that MPTP caused microglial activation both in the striatum and SNc, whereas it increased 3-nitrotyrosine immunoreactivity, an in vivo biomarker of peroxynitrite production, in the SNc but not the striatum. Furthermore, MPTP increased lipid peroxidation product thiobarbituric acid reactive substance in the midbrain, but not the striatum. Edaravone inhibited activation of the microglia and the increased 3-nitrotyrosine immunoreactivity in the SNc but not the striatum, and it also inhibited thiobarbituric acid reactive substance levels in the midbrain. Behavioral analyses showed that edaravone improved MPTP-induced impairment of locomotion and Rotorod performance. These results suggest that edaravone protects against MPTP-induced neurotoxicity in the SNc by blocking the production of reactive oxygen species or peroxynitrite and imply that dopaminergic degeneration in the SNc may play an important role in MPTP-induced motor dysfunction of mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429058     DOI: 10.1124/jpet.106.119206

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease.

Authors:  Bing Li; Dawei Yu; Zhiying Xu
Journal:  J Mol Neurosci       Date:  2013-05-10       Impact factor: 3.444

2.  Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism.

Authors:  Mohammad Moshahid Khan; Smita Zaheer; Ramasamy Thangavel; Margi Patel; Duraisamy Kempuraj; Asgar Zaheer
Journal:  Neurochem Res       Date:  2015-03-10       Impact factor: 3.996

Review 3.  Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions.

Authors:  Linnea R Freeman; Jeffrey N Keller
Journal:  Biochim Biophys Acta       Date:  2011-12-20

4.  Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism.

Authors:  Naoki Inoue; Sae Ogura; Atsushi Kasai; Takanobu Nakazawa; Kazuya Ikeda; Shintaro Higashi; Ayako Isotani; Kousuke Baba; Hideki Mochizuki; Harutoshi Fujimura; Yukio Ago; Atsuko Hayata-Takano; Kaoru Seiriki; Yusuke Shintani; Norihito Shintani; Hitoshi Hashimoto
Journal:  EMBO Rep       Date:  2018-01-25       Impact factor: 8.807

5.  Postnatal manganese exposure alters dopamine transporter function in adult rats: Potential impact on nonassociative and associative processes.

Authors:  S A McDougall; C M Reichel; C M Farley; M M Flesher; T Der-Ghazarian; A M Cortez; J J Wacan; C E Martinez; F A Varela; A E Butt; C A Crawford
Journal:  Neuroscience       Date:  2008-04-07       Impact factor: 3.590

6.  Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease.

Authors:  Akiko Muroyama; Aya Fujita; Cheng Lv; Shota Kobayashi; Yoshiyasu Fukuyama; Yasuhide Mitsumoto
Journal:  Parkinsons Dis       Date:  2012-05-08

7.  Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.

Authors:  Nian Xiong; Jing Xiong; Ghanshyam Khare; Chunnuan Chen; Jinsha Huang; Ying Zhao; Zhentao Zhang; Xian Qiao; Yuan Feng; Harrish Reesaul; Yongxue Zhang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

8.  Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.

Authors:  Wen Ji Yuan; Takao Yasuhara; Tetsuro Shingo; Kenichiro Muraoka; Takashi Agari; Masahiro Kameda; Takashi Uozumi; Naoki Tajiri; Takamasa Morimoto; Meng Jing; Tanefumi Baba; Feifei Wang; Hanbai Leung; Toshihiro Matsui; Yasuyuki Miyoshi; Isao Date
Journal:  BMC Neurosci       Date:  2008-08-01       Impact factor: 3.288

9.  Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.

Authors:  Valerie Joers; Kristine Dilley; Shahrose Rahman; Corinne Jones; Jeanette Shultz; Heather Simmons; Marina E Emborg
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

Review 10.  Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease.

Authors:  Samantha Giordano; Victor Darley-Usmar; Jianhua Zhang
Journal:  Redox Biol       Date:  2013-12-25       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.